Pyrimethamine

Ron Tilles stepped in as CEO of Turing Pharmaceuticals after Martin Shkreli's arrest, facing public and regulatory backlash over Daraprim's 5,000% price hike. Tilles navigated bankruptcy threats, regulatory scrutiny, and media pressure, eventually leading to the company's name change to Vyera Pharmaceuticals. Despite the challenges, Tilles emphasizes the importance of responsible pricing in his current role at Pyros Pharmaceuticals.

FDA expands approval of Novocure's Optune device for metastatic non-small cell lung cancer, despite mixed expert opinions. FDA Commissioner Robert Califf praises GLP-1 drugs as a breakthrough for weight loss and cardiovascular health, though questions their role in addressing obesity's root causes. Bayer CEO Sebastian Guth calls for policy reforms in biopharma ahead of elections. Mark Cuban's entry into drug business inspired by Martin Shkreli's pricing tactics, aiming for transparency. Additional reads cover UnitedHealth's Medicare strategy, bird flu concerns, and gene therapy investment challenges.

Texas A&M University researchers develop 3D-printed medication for pediatric toxoplasmosis, addressing the high cost and lack of dose flexibility in current treatments. Funded by NIH, the project aims to create a novel dose-flexible pediatric delivery system, potentially easing burdens on parents and improving treatment availability.